Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine has announced the initiation of the phase 3 Brexanolone Lifting Outcomes of Moms (BLOOM) study evaluating oral brexanolone (LPCN 1154) for postpartum depression (PPD). The first participant is expected to be dosed in early Q4 2026.

LPCN 1154 is an investigational oral formulation of brexanolone, chemically identical to the naturally occurring neuroactive steroid allopregnanolone, which modulates GABA_A receptors. LPCN 1154 is being developed as a 48-hour, at-home treatment, targeting the need for rapid symptom relief with a short oral regimen.

"We believe a treatment that delivers rapid relief through a 48-hour oral course at home could meaningfully change how women and families manage postpartum depression," said Mahesh Patel, MD, the president and chief executive officer of Lipocine. "BLOOM translates our prior clinical findings and FDA feedback into a study focused on generating the evidence needed to advance LPCN 1154 toward a potential regulatory submission. Our priorities are rigorous execution, clinically meaningful results and disciplined use of capital as we pursue this opportunity for patients and shareholders."

The BLOOM Study

Investigators of the BLOOM study are expected to enroll approximately 120 participants with PPD. It will build on Lipocine’s prior phase 3 trial (NCT06979544).

The outpatient study will use the same 48-hour dosing regimen evaluated in the prior phase 3 trial with primary efficacy endpoint—change from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D17) total score—assessed at 60 hours post dosing initiation. Measures will include periodic review of site populations, third-party support for site selection, geographic diversity, with no selection of sites with significant operational or data quality concerns, and participation by academic sites.

The protocol will include fewer rating scales and assessments, reduced participant contact with site staff, centralized rating for screening and eligibility, and standardized participant eduction about study procedures and assessments. The study includes planned analyses addressing outlier sites and pharmacokinetic data.

Investigators noted that BLOOM is designed to complement the existing LPCN 1154 clinical data package and generate prospective efficacy and safety evidence to support a potential New Drug Application under the 505(b)(2) pathway. The placebo-controlled outpatient study incorporates feedback from a recent meeting with the US Food and Drug Administration (FDA), alongside findings from the prior phase 3 trial.

The Prior Phase 3 Trial

In the prior phase 3 trial, LPCN 1154 did not show a statistically significant reduction from baseline in Hamilton Depression Rating Scale (HAM-D) 17-item total score compared with placebo at hour 60 in the full analysis set, thus failing to meet the primary endpoint.²

However, exploratory post hoc analyses identified anomalies concentrated at one high-enrolling site, including an absence of detectable study drug in blood samples from approximately 40% of LPCN 1154-treated participants at that site. Analyses excluding the site suggested rapid and sustained improvement in participant depressive symptoms.

The prior trial also provided encouraging safety and tolerability findings. No treatment-related severe or serious adverse events were reported, and there were no instances of excessive sedation, loss of consciousness, or treatment discontinuation.

References

1. Lipocine announces initiation of BLOOM phase 3 study of LPCN 1154 for postpartum depression. News release. September 14, 2026. Accessed September 15, 2026. https://www.prnewswire.com/news-releases/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-for-postpartum-depression-302876766.html

2. Kuntz L. LPCN 1154 for postpartum depression fails to meet phase 3 primary endpoint. Psychiatric Times. April 2, 2026. https://www.psychiatrictimes.com/view/lpcn-1154-for-postpartum-depression-fails-to-meet-phase-3-primary-endpoint